Estimated Read Time:

1 minute

SABCS Snippets: Results of the EMBER-3 Trial

SABCS program director Kate Lathrop, MD, talks with Komal Jhaveri, MD, FACP, about the results of phase 3 EMBER-3 trial, which evaluated the role of imlunestrant as monotherapy or in combination with abemaciclib in patients with ER+, HER2- advanced breast cancer whose disease had recurred or progressed during or after an aromatase inhibitor alone or with a CDK4/6 inhibitor.

Share


Recent Posts

Upcoming Key Dates

November 3 – Advance Registration Rates End

November 6 – Child Care Advance Registration Deadline

November 17 – Housing Reservations Close

November 24 – Full Abstract Text Released*

December 1 – SABCS App Available*

December 9 – SABCS 2025 Begins

*approximate dates